BrightSpring Health Services, Inc. Common Stock
BTSG
$45.92
-0.84%
BrightSpring Health Services Inc. is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients, operating within the Medical - Healthcare Information Services industry. The company is a significant platform player in the fragmented home healthcare market, distinct for its integrated model that combines pharmacy solutions with clinical provider services, primarily serving Medicare, Medicaid, and commercially insured populations. The current investor narrative is heavily focused on the company's strategic portfolio optimization and growth trajectory following its recent IPO, with recent headlines highlighting the completion of the sale of its ResCare Community Living business to Sevita, a move intended to sharpen focus on its core Provider Services and Pharmacy Solutions divisions and potentially improve margins.…
BTSG
BrightSpring Health Services, Inc. Common Stock
$45.92
Related headlines
BTSG 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BrightSpring Health Services, Inc. Common Stock's 12-month outlook, with a consensus price target around $59.70 and implied upside of +30.0% versus the current price.
Average Target
$59.70
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$37 - $60
Analyst target range
Analyst coverage for BTSG appears limited, with only 3 analysts providing estimates for revenue and EPS, and no consensus price target or recommendation data provided in the dataset. The implied analyst estimates for the next period show an average EPS of $5.24, ranging from a low of $4.91 to a high of $5.42, and an average revenue estimate of $27.89 billion. The lack of a published consensus target price and the low number of covering analysts typically indicates this is a newer public company (IPO in January 2024) with limited institutional research coverage, which can lead to higher volatility and less efficient price discovery as the investment story is still being established in the public markets.
Bulls vs Bears: BTSG Investment Factors
The bull case, supported by accelerating revenue growth (16.3% YoY), robust free cash flow ($490M TTM), and a compelling PS ratio (0.59x), currently holds stronger evidence than the bear case. However, the investment debate centers on a critical tension: whether the company's dramatic margin improvement and swing to profitability ($77.1M net income in Q4) can be sustained to justify its elevated trailing PE multiple of 39.8x. If margin expansion continues, the forward PE of 22.1x could prove reasonable, but any stumble in profitability would likely trigger severe multiple compression given the stock's high beta of 2.05 and extended technical position.
Bullish
- Explosive Revenue Growth & Momentum: Revenue grew 16.3% YoY in Q4 2025 to $3.55B, with sequential quarterly growth from $2.88B to $3.55B over the year. This accelerating top-line trajectory, coupled with a 137% one-year stock price surge, demonstrates powerful business momentum and market validation of the growth story.
- Strong Profitability & Margin Improvement: The company swung to a $77.1M net profit in Q4 2025 from a net loss in Q3 2024, achieving a 2.17% net margin. Operating margin expanded to 5.87% in Q4, indicating significant operational leverage and successful execution of its strategic portfolio optimization, including the recent ResCare sale.
- Robust Free Cash Flow Generation: Trailing twelve-month free cash flow stands at $490.2M, providing substantial internal liquidity to fund growth and operations. This strong cash generation, supported by a healthy current ratio of 1.57, reduces reliance on external financing and de-risks the balance sheet despite a debt-to-equity ratio of 1.52.
- Attractive Price-to-Sales Valuation: With a PS ratio of 0.59, the stock trades at a significant discount to sales compared to many growth-oriented healthcare peers. This low multiple, combined with 16%+ revenue growth, offers a compelling value proposition if the company can sustain its margin expansion trajectory.
Bearish
- Elevated Valuation on Earnings Basis: The trailing PE ratio of 39.8x is extremely high, having expanded from 24.6x at the end of Q4 2025. While the forward PE of 22.1x suggests expected earnings growth, the current multiple embeds near-perfect execution and leaves little room for disappointment.
- Extreme Volatility & High Beta: With a beta of 2.05, BTSG is more than twice as volatile as the broader market, and it has experienced a maximum drawdown of 20.75% during its uptrend. This high volatility makes it unsuitable for risk-averse investors and increases the likelihood of sharp pullbacks on any negative news.
- Thin & Variable Gross Margins: Gross margin of 11.62% in Q4 2025 is low and has been volatile, ranging from 11.66% to 14.04% over the past year. This margin pressure in a labor-intensive industry highlights operational sensitivity and challenges in achieving consistent profitability at scale.
- Limited Analyst Coverage & Price Discovery: Only 3 analysts provide estimates, with no consensus price target available. This limited coverage for a recent IPO (Jan 2024) leads to less efficient price discovery and higher susceptibility to sentiment swings rather than fundamental analysis.
BTSG Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 137.07% one-year price change. With a current price of $43.10, it is trading at approximately 95% of its 52-week high of $45.59, positioning it near the top of its annual range, which signals strong momentum but also raises concerns about potential overextension and vulnerability to profit-taking. Recent momentum shows acceleration, with a 6.03% gain over the past month and a 12.24% gain over the past three months, both significantly outpacing the broader market's negative returns (SPY down -4.28% and -4.0%, respectively), indicating robust relative strength and a continuation of the longer-term bullish trend. Key technical support is anchored at the 52-week low of $15.48, while immediate resistance is at the 52-week high of $45.59; a decisive breakout above this level could signal a new leg higher, while a failure could lead to consolidation. The stock's beta of 2.05 indicates it is more than twice as volatile as the broader market, a critical factor for risk management, especially given the recent 20.75% maximum drawdown figure, which underscores the potential for sharp pullbacks within the uptrend.
Beta
2.05
2.05x market volatility
Max Drawdown
-20.8%
Largest decline past year
52-Week Range
$15-$47
Price range past year
Annual Return
+153.1%
Cumulative gain past year
| Period | BTSG Return | S&P 500 |
|---|---|---|
| 1m | +11.1% | +0.4% |
| 3m | +22.4% | -2.0% |
| 6m | +61.9% | +4.1% |
| 1y | +153.1% | +23.9% |
| ytd | +19.6% | -0.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BTSG Fundamental Analysis
Revenue growth is robust and accelerating, with Q4 2025 revenue of $3.55 billion representing a 16.31% year-over-year increase, and sequential quarterly revenue has grown from $2.88 billion in Q1 to $3.55 billion in Q4, demonstrating strong momentum. The company is profitable, with Q4 2025 net income of $77.08 million and a net margin of 2.17%, showing a clear improvement from the net loss of $8.23 million in Q3 2024; gross margin for the quarter was 11.62%, which, while low, has been relatively stable in recent quarters, and operating income of $208.32 million indicates a 5.87% operating margin. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.52, but financial health is supported by strong cash generation, with trailing twelve-month free cash flow of $490.17 million and a current ratio of 1.57, providing solid liquidity to fund operations and growth internally without immediate external financing needs.
Quarterly Revenue
$3.6B
2025-12
Revenue YoY Growth
+0.16%
YoY Comparison
Gross Margin
+0.11%
Latest Quarter
Free Cash Flow
$490169000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BTSG Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is elevated at 39.79x, while the forward PE is significantly lower at 22.05x, indicating the market is pricing in substantial earnings growth expectations for the coming year. Compared to sector averages, the stock's Price-to-Sales (PS) ratio of 0.59 is a key point of comparison; while direct industry averages are not provided in the data, a sub-1.0 PS ratio is often considered value-oriented for a growing business, especially when contrasted with its own elevated PE, suggesting the market may be valuing it on a sales basis due to its currently thin net margins. Historically, the stock's own trailing PE ratio has expanded dramatically from 24.60x at the end of Q4 2025 to the current 39.79x, placing it near the top of its observable historical range and indicating the market has become significantly more optimistic about its future earnings power, embedding high expectations into the current price.
PE
39.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -89x~118x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: BTSG's primary financial risk stems from its elevated valuation on an earnings basis (39.8x trailing PE) despite thin and volatile gross margins of 11.6%. The company's debt-to-equity ratio of 1.52 indicates moderate leverage, though this is mitigated by strong free cash flow generation of $490M TTM. Earnings volatility remains a concern, as evidenced by the swing from a $8.2M net loss in Q3 2024 to a $77.1M profit in Q4 2025—the investment thesis depends heavily on maintaining this newfound profitability trajectory.
Market & Competitive Risks: The stock faces significant valuation compression risk, trading near its 52-week high with a trailing PE that has expanded 62% since late 2025. With a beta of 2.05, BTSG is highly sensitive to broader market downturns and sector rotation away from growth stocks. Competitive risks in the fragmented home healthcare market are substantial, though the company's integrated pharmacy-provider model provides some differentiation. Regulatory headwinds affecting Medicare/Medicaid reimbursement, which comprise a significant portion of revenue, represent an ongoing external threat.
Worst-Case Scenario: The most damaging scenario would involve a combination of margin compression (gross margins falling below 10%), a growth deceleration below 10% YoY, and a broader market correction affecting high-beta stocks. This could trigger analyst downgrades (though coverage is limited) and rapid multiple compression toward the stock's 52-week low of $15.48. A more realistic severe downside from the current $43.10 would be a return to recent support around $38 (a -12% decline) or, in a full bear market for growth stocks, a test of the $30 level (-30% decline), aligning with the stock's demonstrated 20.75% maximum drawdown during its uptrend.